Baird Maintains Outperform on Maravai LifeSciences, Lowers Price Target to $11
Portfolio Pulse from jenniferd'souza@benzinga.com
Baird analyst Catherine Schulte maintains an Outperform rating on Maravai LifeSciences (NASDAQ:MRVI) but lowers the price target from $18 to $11.
August 08, 2023 | 1:01 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Baird analyst Catherine Schulte maintains an Outperform rating on Maravai LifeSciences but lowers the price target from $18 to $11.
The news is directly related to Maravai LifeSciences. While the Outperform rating is maintained, the lowering of the price target from $18 to $11 might create some uncertainty among investors, potentially impacting the stock's short-term performance.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100